No Data
Be Wary Of Winner Medical (SZSE:300888) And Its Returns On Capital
Winner medical (300888.SZ): Excluding infection protection products, the gross margin for medical routine products achieved 40% in the first three quarters.
On December 9th, Glonghui reported that Winner Medical (300888.SZ) stated on the investor interaction platform that since the outbreak of public health events, the medical business has transitioned from the impact of a high base to normalized operation. The proportion of high gross margin and high growth products (such as high-end dressings and personal health care products) within the entire medical sector is gradually increasing. Excluding infection protection products, the cumulative gross margin for conventional medical products in the first three quarters has reached 40%, and it is expected to maintain this level. On the cost side, with the steady increase in sales growth, fixed costs are expected to be shared, and on the marketing side, we will strengthen ROI control to enhance the precision of expense allocation.
Winner Medical (300888.SZ): Cumulatively, in the first three quarters of 2024, foreign sales accounted for 45% of the medical sector's revenue.
On December 9, Glonghui reported that winner medical (300888.SZ) stated on the investor interaction platform that it has been engaged in export business for 33 years, accumulating rich market experience. After returning to normal, in the first three quarters of 2024, foreign sales accounted for 45% of the medical sector's revenue, and there is great growth potential for this business in the future. The company announced the acquisition project of GRI in late September 2024, which has multiple strategic significances: on one hand, GRI has production bases in china, usa, Vietnam, and the Dominican Republic, and winner medical will utilize its global production bases for optimization.
Winner Medical (300888.SZ): The cumulative sales of infection protection products in the first three quarters were 0.26 billion yuan, accounting for 10% of the scale of medical business income.
Winner Medical (300888.SZ) stated in a recent investor relations event that currently, the main sales of infection protection products are flat masks, and the market still has normal demand, with a solid business foundation. The company has also launched many new products this year, such as cotton-lined masks, biodegradable masks, which provide more comfort when worn and are also more eco-friendly. With the promotion of innovations and sales initiatives, as of the first three quarters of 2024, cumulative sales of infection protection products totaled 0.26 billion yuan, accounting for 10% of the scale of medical business revenue.
Winner Medical (300888.SZ) granted 6.9763 million restricted stocks at a grant price of 15.39 yuan per share.
Winner Medical (300888.SZ) announced that the board of directors and the supervisory board have approved "Regarding the 2024...
Winner Medical Co., Ltd.'s (SZSE:300888) Top Holders Are Insiders and They Are Likely Disappointed by the Recent 3.3% Drop
Winner Medical Co., Ltd.'s (SZSE:300888) Price Is Right But Growth Is Lacking
No Data
